Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib Plus Pembrolizumab in Metastatic Uveal Melanoma
NCT05308901Phase 2Terminated
- Start
- Aug 2022
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib, pembrolizumab in Uveal melanoma (UM). Started Aug 2022; status: terminated.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT05308901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05308901.